Study ACA-ARGE-04-001 "A Pilot, Open-Label Study Assessing Safety, Tolerability, Efficacy of a Simplified Lopinavir/Ritonavir Induction/Maintenance Therapy in HIV-Infected Subjects on Their First Protease Inhibitor-Based Regimen".
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 发起方
- 入组人数
- 100
- 试验地点
- 4
- 主要终点
- Proportion of patients remaining undetectable below 50 copies/mL at 48 weeks
研究概览
简要总结
This study will assess the safety, tolerability and antiviral activity of a simplified PI-based treatment regimen (Kaletra,ä) compared to conventional HAART regimens in patients infected with HIV-1 who are on their first boosted-PI antiretroviral treatment regimen.
The potency of the antiviral activity of Kaletra has been clearly demonstrated in a wide spectrum of patients in a number of different clinical trials.6-9 The durable viral suppression seen after 4 years of therapy10 proves that it can provide effective, long-term treatment for people with HIV-1.
Data from one of these trials (M97-720),6 an ongoing Phase II study of lopinavir/ritonavir in combination with NRTIs suggests there may be a role for monoclass therapy with Kaletra in the treatment of HIV-1-infection.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Subject has confirmed his or her willingness to participate in this study after being informed of all aspects of the trial that are relevant to his or her decision to take part, by signing and dating the IRB / IEC approved informed consent form.
- •Subject is HIV positive and on their first antiretroviral treatment regimen, based on any two NRTIs plus lopinavir/ritonavir or a ritonavir-boosted PI combination. Subject must have had no previous exposure to other regimens.
- •Subject has a viral load <50 copies/ml at the time of baseline evaluation for at least 6 months.
- •Subject has a CD4 cell count ³ 100 cells/mm
- •Subject is aged >18 years.
- •Vital signs, physical examination and laboratory results do not exhibit evidence of acute illness.
- •Subject has not been treated for an active opportunistic infection within 30 days of screening.
- •If female, subject has a negative pregnancy test and agrees to use, for the duration of the study, a barrier method of birth control that has a history of proven reliability as judged by the investigator.
- •Subject does not require and agrees not to take, for the duration of the study, any medication that is contraindicated with any of the antiretroviral drugs in their treatment regimen. The subject agrees not to take any medication, including over-the-counter medicine, alcohol, or recreational drugs without the knowledge and permission of the principal investigator
排除标准
- •Subject has current uncontrolled substance abuse or psychiatric illness that could preclude compliance with the protocol.
- •Subject has a viral load of > 50 copies/ml
- •Subject is HBsAg +
- •Subject has active tuberculosis or an opportunistic infection.
- •Subject has active malignancy (except Kaposi's Sarcoma).
- •Subject has liver failure as evidenced by ALT / AST > 5 x Upper Limit of Normal (ULN).
- •Female subject is pregnant or lactating.
- •Subject has received an investigational drug within 30 days prior to the initiation of the study.
- •Subject has modified his/her antiretroviral therapy during the 3 months prior to baseline or is intending to do so during the course of the study.
研究组 & 干预措施
Lopinavir/ritonavir monotherapy
Patients with undetectable viral load while on 1st line ARV therapy will be randomized to the expermental arm: Lopinavir/ritonavir monotherapy
干预措施: Lopinavir/ritonavir simplification strategy (Drug)
Lopinavir/Ritonavir plus 2 NRTIs
Patients randomized to this arm will continue with standard of care triple therapy, based on Lopinavir/Ritonavir plus 2 NRTIs
干预措施: Lopinavir/ritonavir simplification strategy (Drug)
结局指标
主要结局
Proportion of patients remaining undetectable below 50 copies/mL at 48 weeks
时间窗: 48 weeks
次要结局
未报告次要终点
研究者
Pedro Cahn
Scientic Director, The Huesped Foundation
Fundación Huésped